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OBJECTIVE — There is limited information from large-scale prospective studies regarding
the prediction of type 1 diabetes by speciﬁc types of pancreatic islet autoantibodies, either alone
orincombination.Thus,westudiedtheextenttowhichspeciﬁcautoantibodiesarepredictiveof
type 1 diabetes.
RESEARCH DESIGN AND METHODS — Two cohorts were derived from the ﬁrst
screening for islet cell autoantibodies (ICAs) in the Diabetes Prevention Trial–Type 1 (DPT-1).
Autoantibodies to GAD 65 (GAD65), insulinoma-associated antigen-2 (ICA512), and insulin
(micro-IAA [mIAA]) were also measured. Participants were followed for the occurrence of type
1 diabetes. One cohort (Questionnaire) included those who did not enter the DPT-1 trials, but
responded to questionnaires (n  28,507, 2.4% ICA
). The other cohort (Trials) included
DPT-1 participants (n  528, 83.3% ICA
).
RESULTS — In both cohorts autoantibody number was highly predictive of type 1 diabetes
(P  0.001). The Questionnaire cohort was used to assess prediction according to the type of
autoantibody. As single autoantibodies, ICA (3.9%), GAD65 (4.4%), and ICA512 (4.6%) were
similarly predictive of type 1 diabetes in proportional hazards models (P  0.001 for all).
However, no subjects with mIAA as single autoantibodies developed type 1 diabetes. As second
autoantibodies, all except mIAA added signiﬁcantly (P  0.001) to the prediction of type 1
diabetes. Within the positive range, GAD65 and ICA autoantibody titers were predictive of type
1 diabetes.
CONCLUSIONS — Thedataindicatethatthenumberofautoantibodiesispredictiveoftype
1 diabetes. However, mIAA is less predictive of type 1 diabetes than other autoantibodies.
Autoantibody number, type of autoantibody, and autoantibody titer must be carefully consid-
ered in planning prevention trials for type 1 diabetes.
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A
utoantibodies to islet cell antigens
are known predictors of type 1 dia-
betes and are commonly present at
its diagnosis (1–12). Islet cell autoanti-
bodies (ICAs), the ﬁrst identiﬁed (1,2),
actually represent autoimmunity to sev-
eral different antigens. More recently, au-
toantibodies speciﬁc to single tissue
antigens, termed biochemical autoanti-
bodies, have been identiﬁed (4,7,8,11–
13). These include antibodies to GAD 65
(GAD65), the antibody to an insulinoma-
associated antigen-2 (ICA512), and anti-
bodies to insulin (IAA).
Type1diabetespreventiontrialshave
usedautoantibodiestoscreenforindivid-
uals at increased risk who might be can-
didates for participation (14–16). The
Diabetes Prevention Trial–Type 1
(DPT-1) assessed parenteral and oral in-
sulin as potential prevention modalities.
First- and second-degree relatives of type
1 diabetic patients were screened for the
presence of ICA, which was required for
eligibility. Although not relevant to the
trials, biochemical autoantibodies were
subsequently measured from screening
samples to learn more about their predic-
tion of type 1 diabetes. The prevalence of
autoantibodies according to various sub-
groups has been reported for DPT-1 (17).
WeusedtwoDPT-1cohortstoexam-
ine the prediction of type 1 diabetes by
ICA and biochemical autoantibodies, as
few large-scale studies have examined the
prediction of type 1 diabetes by a variety
of single autoantibodies in large numbers
of individuals of whom many ultimately
developedtype1diabetes.Onecohortin-
cludes DPT-1 participants who partici-
pated in the trials (the Trials cohort), and
the other cohort includes participants
who did not participate in either trial but
responded to questionnaires (the Ques-
tionnaire cohort) used to ascertain infor-
mation regarding the diagnosis of type 1
diabetes. The differing perspectives of
thesetwocohortsandthelargenumberof
individuals studied, almost 30,000, pro-
vide a unique opportunity for studying
the prediction of type 1 diabetes by
autoantibodies.
RESEARCH DESIGN AND
METHODS— All participants were
relatives of patients with type 1 diabetes.
There were 97,273 serum samples col-
lected and tested for ICA at the initial
screening. Informed consent was ob-
tained from all subjects. As described
elsewhere (14,15), eligibility for the trials
was further assessed on the basis of met-
abolic abnormalities (parenteral insulin
trial)andthepresenceofIAA(oralinsulin
trial). There were 711 individuals who
participated in the DPT-1 trials. Of the
screening samples, 84% were later tested
for the presence of GAD65, ICA512, and
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(mIAA).
Questionnaires were mailed to
79,292 individuals who did not enter the
trials.ThosewhowereICA
didnotmeet
the criteria for trial entry or chose not to
enter the trials. Responses were received
from 37,017 subjects. Those who had all
autoantibody determinations and sufﬁ-
ciently complete data were included in
the analyses (n  29,035).
Procedures
Questionnaire cohort. Participants
were asked whether they were informed
by a physician that they had developed
type 1 diabetes. If participants answered
afﬁrmatively, they were asked when they
received the diagnosis. The follow-up in-
tervalwasthetimebetweenthedateofthe
response to the questionnaire and the
date of the initial screen for autoantibod-
ies (those who did not develop type 1 di-
abetes)orbetweenthedateofdiagnosisas
indicated on the questionnaire and the
date of the initial screen (those who de-
veloped type 1 diabetes). The mean  SD
age of the individuals in the Question-
naire cohort (n  28,507) was 17.9 
13.0 years (55% female). The duration of
follow-up was 4.2  2.4 years.
Trials cohort. The procedures for the
DPT-1 trials have been described else-
where(14,15).Inboththeparenteraland
oral insulin trials, oral glucose tolerance
tests were scheduled for 6-month inter-
vals. Blood samples were obtained for
plasma glucose and C-peptide measure-
ments in the fasting state and at 30, 60,
90, and 120 min. Those with glucose val-
ues in the diabetic range (fasting glucose
126 mg/dl and/or 2-h glucose 200
mg/dl) were asked to return for conﬁrma-
tion at a follow-up visit. The follow-up
interval was the time between the date of
lastcontactandthedateoftheﬁrstscreen
(those who did not develop type 1 diabe-
tes) or the time between the date of diag-
nosisandthedateoftheﬁrstscreen(those
who developed type 1 diabetes). In 61%
ofthosewithtype1diabetesintheDPT-1
trials, diabetes was diagnosed at a routine
visit. In others, diabetes was diagnosed
clinically. There was no overall effect of
the intervention in either trial (14,15).
The mean  SD age of those in the Trials
cohort (n  528) was 12.2  9.3 years
(43% female). The Trials cohort was sig-
niﬁcantly younger and had a lower pro-
portion of female participants than the
Questionnaire cohort (P  0.001 for
both). The duration of follow-up was
4.4  2.2 years.
Laboratory measures
ICA. ICA values were determined by an
immunoﬂuorescence assay on frozen sec-
tions of blood type O human pancreas in
the DPT-1 ICA Core Laboratory (Gaines-
ville, FL, February 1994–September
1997 and January 1999–October 2003;
New Orleans, LA, September 1997–
January 1999). ICA values of 10 Juve-
nile Diabetes Foundation (JDF) units
wereconsideredpositive.Inthe1995Im-
munology of Diabetes Society workshop
(18), this ICA assay had a speciﬁcity of
100% and a sensitivity of 74.4% for pa-
tientswithnew-onsettype1diabeteswho
were aged 30 years. Based on a receiver
operating characteristic curve, in this
datasetwithapositiveJDFvalueof10,the
assay sensitivity was 75.0% with a 95.7%
speciﬁcity (no age inﬂuence on the val-
ues).
GAD65, ICA512, and mIAA. Autoan-
tibodies against GAD65 and ICA512bdc
(ICA512) were determined at the Barbara
Davis Center (Denver, CO). IAA (using
the micro-volume requiring assay) values
were determined at the Barbara Davis
Center or the Joslin Diabetes Center (Bos-
ton,MA).Asdescribedpreviously,acom-
binedGAD65andICA512radioassaywas
performed (19). Labeled recombinant
GAD65 and ICA512 autoantibodies were
produced by in vitro transcription/
translation with differential labeling
([
3H]GAD65 and [
35S]ICA512) (8,13).
Thelevelsofbothautoantibodieswereex-
pressed as an index. The upper limits of
normal (0.032 for GAD65 and 0.049 for
ICA512)wereestablishedasthe99thper-
centile for GAD65 and for ICA512 from
receiver operating characteristic curves in
198 healthy control subjects and 50 pa-
tients with new-onset diabetes. In this
dataset,aGAD65indexof0.032(usedfor
the analysis) provided a 41.8% sensitivity
and a 98.3% speciﬁcity (no difference by
age-group), and for ICA512 an index of
0.049 (used for the analysis) resulted in a
sensitivity of 57.5% and speciﬁcity of
98.5% (no difference by age-group). In
the 2000, 2002, and the 2003 Diabetes
Antibody Standardization Program
(DASP) for proﬁciency testing, the sensi-
tivity/speciﬁcityresultsfortheGAD65as-
say were 84%/96%, 90%/93%, and 84%/
98% and for the ICA512 assay were 52%/
100%, 62%/99%, and 58%/100%,
respectively.Theinterassaycoefﬁcientsof
variation for ICA512 and GAD65 were 8
and 10%, respectively.
The mIAA assay (20) was performed
as described and expressed as an index
with the upper limits of 0.02 and 0.01
(Boston and Denver laboratories, respec-
tively) based on the 99th percentile of
healthy control values. In the combined
dataset, a positive index value had 36.8%
sensitivity and 92.7% speciﬁcity. Deter-
mination of mIAA on samples began later
thanforGAD65andICA512(assaydevel-
opment needed). In the 2003 DASP pro-
ﬁciency testing, the sensitivity for the
mIAA assay was 74 and 56% and the
speciﬁcity was 90 and 98%, respectively,
for the Denver and Boston laboratories.
The correlation coefﬁcient between both
laboratories was r  0.90 (P  0.0001).
The interassay coefﬁcient of variation for
mIAA was 16%.
Data analysis
Student t tests and 
2 tests were used to
compare groups. The log-rank test was
usedtocomparethedistributionsofevent
times between groups. Cox proportional
hazards regression models were used to
examine effects on type 1 diabetes risk
over time. The Kaplan-Meier estimate of
the survival function was used to obtain
estimates of type 1 diabetes occurrence.
Spearman correlations were performed to
assess associations. Log transformations
were performed for certain analyses.
SAS (version 9.1.3) was used for the
analyses. All P values are two-sided. The
level of signiﬁcance was P  0.05.
RESULTS— The prevalence of each
autoantibody at the initial screening is
shown in Table 1 for both cohorts. Auto-
antibody prevalence was much higher in
the Trials cohort, which is attributable
to the selection for ICA positivity and
for the additional trial entry criteria. Al-
though some of those in the Trials co-
hort were ICA
 at the initial screening,
Table1—Prevalenceofpositiveautoantibod-
ies at initial screening
Questionnaire
cohort
Trials
cohort
n 28,507 528
ICA 674 (2.4) 440 (83.3)
GAD65 907 (3.2) 363 (68.8)
ICA512 315 (1.1) 258 (48.9)
mIAA 525 (1.8) 136 (25.8)
Data are n or n (%).
Type 1 diabetes prediction by autoantibodies
2270 DIABETES CARE, VOLUME 32, NUMBER 12, DECEMBER 2009 care.diabetesjournals.orgFigure 1—Curves indicate the occurrence of type 1 diabetes (T1D) over follow-up according to the number of autoantibodies present at the initial
screeningintheQuestionnairecohort(A),intheTrialscohort(B),andinthecohortscombined(C).Inallthreepanels,thereweresigniﬁcanttrends
among the groups of an increasing occurrence of type 1 diabetes with increasing autoantibody number. The numbers (1–4) indicate the number of
autoantibodies. (The fraction in parentheses indicates the number who developed type 1 diabetes among the number in the group at baseline.)
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 before ran-
domization.
In the Questionnaire cohort, ICA512
positivity was most commonly associated
with one or more autoantibodies (65%),
whereas mIAA positivity was least com-
monlyassociatedwithotherautoantibod-
ies(22%).ThepercentagesofGAD65and
ICA positivity with associated autoanti-
bodies were 37 and 39%, respectively.
The occurrence of type 1 diabetes ac-
cordingtothenumberofbiochemicalauto-
antibodies is shown separately for the
QuestionnaireandTrialscohortsandinthe
aggregate in Fig. 1. In each cohort, there
tended to be an increasing occurrence of
type 1 diabetes as the number of autoanti-
bodies increased (P  0.001 for both).
The occurrence of type 1 diabetes
among those with a single autoantibody is
shown in Table 2 for the Questionnaire co-
hort. None of the 407 individuals with the
presence of only mIAA developed type 1
diabetes. The occurrence of type 1 diabetes
was similar for those with GAD65 alone
(4.4%), ICA512 alone (4.6%), and ICA
alone(3.9%).Inproportionalhazardsmod-
els, there were signiﬁcant associations be-
tweentheoccurrenceoftype1diabetesand
each of those autoantibodies occurring sin-
gly(P0.001forall).Whenagewasadded
as a covariate, the associations remained
highly signiﬁcant (P  0.001).
Supplemental Table A1 (available at
http://care.diabetesjournals.org/cgi/
content/full/dc09-0934/DC1) shows the
occurrence of type 1 diabetes among
those who were single autoantibody–
positive in the combined Questionnaire
andTrialscohorts.Theoccurrenceoftype
1 diabetes for those with ICA alone was
somewhat higher than the occurrence for
the other autoantibodies alone.
The distribution of mIAA values was
examined to determine whether the lack
of occurrence of type 1 diabetes in those
with mIAA alone could be the result of a
preponderance of low titers. Because
mIAAsweremeasuredintwolaboratories
(positive results: n  123 for Boston and
n  284 for Denver) and the threshold
was higher for an abnormal value in Bos-
ton than in Denver (0.02 vs. 0.01), the
distributions were examined for each lab-
oratory. Among those with abnormal val-
ues, the median values for Boston and
Denver were 0.108 and 0.024, respec-
tively. The values for the 75th percentiles
were0.182and0.051,respectively.Thus,
an appreciable proportion of the titers
was clearly elevated.
Figure 2 shows the effect of adding
each autoantibody as a second autoanti-
body to the presence of a single autoanti-
body (any of the other three). When ICA,
ICA512, or GAD65 was each included as
a second autoantibody, the occurrence of
type 1 diabetes was signiﬁcantly greater
(P0.001foreach)thanwhentherewas
single autoantibody positivity. However,
with mIAA as a second autoantibody
there was no signiﬁcant difference from
the presence of one autoantibody. (There
was little difference in risk increment be-
tween GAD65 and ICA when either was
the ﬁrst autoantibody and the other was
added [data not shown].) When each of
the autoantibodies was present addition-
ally as a third autoantibody (supplemen-
tal Fig. A1, available in an online
appendix), the risk increased appreciably
with ICA and ICA512 (both P  0.001)
but did not increase signiﬁcantly with
GAD65 and mIAA.
The Trials cohort was used to assess
the inﬂuence of a second autoantibody
besides ICA. There was an increase in the
percentage of those developing type 1 di-
abetes when GAD65 and ICA512 each
waspresentbesidesICA(ICAalone:13of
65 [20%], ICA with GAD65: 30 of 87
[34%], and ICA with ICA512: 11 of 22
[50%]).However,whenagewasincluded
as a covariate in proportional hazards
models,neithertheadditionalpresenceof
GAD65 nor that of ICA512 was signiﬁ-
cant. The numbers for the additional
presence of mIAA as a second autoanti-
body were too small for a meaningful
analysis; however, 3 of 6 (50%) devel-
oped type 1 diabetes.
Associations of autoantibody titers
were examined in the combined cohorts.
Of those who did not develop type 1 dia-
betes (n  28,652), ICA512 and GAD65
titersweremuchmorestronglycorrelated
(r  0.31) than the titers of any other
autoantibody pair (r ranged from 0.03 to
0.13). However, among those who devel-
oped type 1 diabetes (n  383), although
theICA512-GAD65correlationremained
similar (r  0.30), the correlations of
other autoantibody pairs tended to in-
crease, especially when the pair included
an ICA titer (with ICA titer: r  0.39 for
GAD65 titer, r  0.51 for ICA512 titer,
and r  0.34 for mIAA titer). In this large
dataset, all correlations were signiﬁcant
(P  0.001 for all).
The association between the develop-
ment of type 1 diabetes and titer (log-
transformed) was examined among those
who were positive for single autoantibod-
ies in the combined cohorts. Because of
the lack of cases of type 1 diabetes for
those with mIAA positivity alone, the
analysis was not performed for that auto-
antibody. GAD65 titer (type 1 diabetes/
total  27 of 582) and ICA titer (29 of
472) were each predictive of type 1 dia-
betes (P  0.01 for both, with and with-
out age as a covariate). There was
borderlinesigniﬁcance(P0.04andP
0.07 with age added) for the ICA512 titer
(6 of 113), but the number for that
analysis was small.
CONCLUSIONS — The analyses
presented above were designed speciﬁ-
cally to discern the extent to which posi-
tivity for a single autoantibody predicts
the occurrence of type 1 diabetes. They
showed that among those in the Ques-
tionnaire cohort, ICA, ICA512, and
GAD65,assinglepositiveautoantibodies,
were similarly predictive of type 1 diabe-
tes. In addition, each of those autoanti-
bodies appeared to add signiﬁcant
increments of risk when they were in-
cluded as second autoantibodies in the
Questionnaire cohort. However, type 1
diabetes was not associated with mIAA as
a single autoantibody, and the inclusion
of mIAA as a second or a third autoanti-
body appeared to have little effect. The
addition of single biochemical autoanti-
bodies to ICA in the Trials cohort did not
signiﬁcantly increase type 1 diabetes risk
with age included as a covariate. This
ﬁnding could be related to the selection
criteria for that cohort and to the small
numbers.
The ﬁndings from this study are bet-
terunderstoodbyconsideringtheminthe
context of the characteristics of each co-
hort. The vast majority of those in the
Questionnaire cohort were ICA
 at the
initialscreening,whereasthoseintheTri-
als cohort were mostly ICA
 at the initial
Table 2—Associations of type 1 diabetes oc-
currence with the presence of single autoan-
tibodies in the Questionnaire cohort at initial
screening
Type 1
diabetes/total
(%) HR (95% CI)
GAD65 25/568 (4.4) 27.6 (16.8–45.4)*
ICA512 5/110 (4.6) 29.5 (11.6–74.7)*
mIAA 0/407 (0) —
ICA 16/407 (3.9) 27.5 (15.4–49.0)*
Reference group: negative for all autoantibodies
(type 1 diabetes/total  41 of 26,651). *P  0.001.
Type 1 diabetes prediction by autoantibodies
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itivebeforerandomization.Moreover,the
Trials cohort was selected for additional
characteristics, including metabolic im-
pairment and IAA positivity. These fac-
tors, together with glucose tolerance test
surveillance in that cohort, could explain
the relatively stronger association of type
1 diabetes with single positivity of ICA
when the cohorts were combined.
The ﬁnding that autoantibody num-
ber predicts type 1 diabetes is consistent
with other studies (9,15). The lack of a
mIAA effect was similar to a previous
ﬁnding of little effect when IAA was in-
cluded as a third autoantibody (21).
However, there have been other studies
that showed a higher risk associated with
IAA positivity (15,22,23). Other autoan-
tibodies, either accounted for or unac-
counted for, could have explained these
associations. ICA
 individuals who were
also IA-2A
 have been observed to have a
high risk for type 1 diabetes (11). The
addition of ICA to other autoantibodies
has been shown to substantially increase
the risk of type 1 diabetes in ﬁrst-degree
relatives (24). An autoantibody to zinc
transporter 8 has recently been found to
be predictive of type 1 diabetes in chil-
dren (12).
The percentages of common positiv-
ity with at least one other autoantibody
ranged from 22% for mIAA to 65% for
ICA512. In addition, the correlations of
titers between autoantibody pairs dif-
fered, and the correlations varied accord-
ing to the subsequent development of
type 1 diabetes. It is possible that associ-
ationsamongautoantibodiesaccordingto
positivity and titer are a function of the
stage of progression to type 1 diabetes in
the study population. If so, the serial fol-
low-up of these associations could pro-
vide insight into both the prediction and
pathogenesis of type 1 diabetes.
Among those with single positivity of
GAD65 and ICA, type 1 diabetes was pre-
dicted by titer. Thus, titers can provide
useful information, even within the posi-
tive range. In a previous report, among
those with positive autoantibodies, the ti-
ters of IA-2 antigen and IAA were both
predictive of type 1 diabetes (25).
IAA has been the most difﬁcult to
measure in multiple DASP workshops.
Although a cutoff is set at the 99th per-
centile for each of the autoantibodies, the
strength of signal for IAA of patients with
new-onset type 1 diabetes is much closer
to the range of signal for normal control
subjects compared with that for either
Figure 2—Curves indicate the occurrence of type 1 diabetes (T1D) in the Questionnaire cohort
over follow-up for the presence of one autoantibody and for the additional presence of a second
autoantibodyattheinitialscreening.Thus,ineachpanelthegroupsthatincludedaspeciﬁcsecond
positive autoantibody were compared with the group that had one positive autoantibody from any
of the others. The panels show that when ICA (A), GAD65 (B), or ICA512 (C) each was present
as a second autoantibody, there were signiﬁcant and similar increases in the occurrence of type 1
diabetes; however, there was no increase when mIAA was present as a second autoantibody (D).
The number shown for each curve (1, 2) indicates the number of autoantibodies. Proportions of
those who developed type 1 diabetes are shown for each curve. (The fraction in parentheses
indicates the number who developed type 1 diabetes among the number in the group at baseline.)
Orban and Associates
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it is possible that a sizable proportion of
mIAA
 values represents false-positive
resultsorlow-afﬁnityIAAassociatedwith
lowerrisk(26).Becauseconﬁrmationand
persistence were not determined in the
currentstudy,thesefactorswillbeimpor-
tant to evaluate in future studies.
The ﬁndings in this study might not
be fully generalizable because they were
derived from relatives of patients with
type 1 diabetes. As discussed above, the
Trials cohort was selected on the basis of
certain criteria. In addition, the composi-
tion of the Questionnaire cohort could
have been inﬂuenced by the willingness
to respond to the questionnaire and even
tosomeextentbytheabsenceofthequali-
fying criteria for entry into the trials. As
discussed above, the increased occur-
rence of type 1 diabetes in the Trials co-
hort is probably attributable to selection
factors for trial entry and to oral glucose
tolerance test surveillance.
Our ﬁndings show that although au-
toantibodynumberisapredictoroftype1
diabetes,theparticulartypeandtiterofan
autoantibody can inﬂuence prediction.
Moreover, it is evident that the frequen-
cies and the associations of autoantibod-
ies with each other can vary to a great
extent. These factors must be carefully
considered in planning prevention trials
for type 1 diabetes.
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